Gepaktiv vs other drugs for fatty liver with enlarged liver
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 18 and 65.
- You have been diagnosed with metabolic fatty liver disease (related to your weight or metabolism).
- An ultrasound shows your liver is at least 3 cm larger than normal.
- Your blood ALT levels (a liver enzyme) are between 90 and 150 U/L.
- A FibroScan test shows your liver fat score is 260 dB/m or higher, and your liver stiffness (a measure of scarring) is 11 kPa or higher.
- You can attend all visits and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
This trial tests whether diacerein can help people with metabolic dysfunction-associated fatty liver disease (MASLD). It may reduce liver fat and improve liver health. If you have this condition, this study may offer a new treatment option.
This study tests an investigational supplement called Godex Carnitine Orotate Complex to see if it helps people with nonalcoholic fatty liver disease (NAFLD) lower their liver enzymes and reduce liver fat. It may be a good option if you have elevated liver enzymes and evidence of fat in your liver.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study is testing ways to prevent and treat liver scarring (fibrosis) caused by a condition called MAFLD, which is a buildup of fat in the liver. If you have this condition and some liver scarring, this trial may offer a chance to help manage it.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.